Immunotherapy in Squamous Cell Cancer of the Esophagus.
Treatment of esophageal carcinoma has changed dramatically following several landmark trials, which have proven the benefit of immunotherapy. The selective PD-1 (programmed cell death ligand-1)-inhibitor nivolumab has been shown to improve DFS in the adjuvant therapy setting (CheckMate-577). In the...
| Published in: | Current Oncology Vol. 29; no. 4; pp. 2461 - 2472 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Published: |
MDPI
Apr2022
|
| Online Access: | View this record in EBSCOhost |